Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A study from TIL pioneer Rosenberg supports a path for therapies based on peripheral T cells

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those in their circulation.

Clinical studies led by NCI Chief of Surgery Steven Rosenberg have shown

Read the full 502 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE